Filing Flows

Filing Flows › Corcept Therapeutics (CORT) › Who owns the stock

Who owns Corcept Therapeutics (CORT) stock

421 funds reported Corcept Therapeutics (CORT) shares in their latest 13F filings, worth $7.4B in all. The largest holder is BlackRock ($1.1B). Last quarter 241 funds added to their stakes and 153 cut them.

Largest holders of CORT (13F)Largest holders of CORT (13F)BlackRock$1.1BIngalls & Snyder LLC$690MRenaissance Technologies LLC$457MVanguard Portfolio Management LLC$439MVanguard Capital Management LLC$363MParallel Advisors, LLC$345MVanguard Group$330MFMR LLC$290MState Street$285MAQR Capital Management LLC$225M

Largest holders (13F)

FundSharesValueChangeQuarter
BlackRock12,432,023$1.1Bincrease2026-06-30
Ingalls & Snyder LLC7,934,507$690Mincrease2026-06-30
Renaissance Technologies LLC5,261,628$457Mdecrease2026-06-30
Vanguard Portfolio Management LLC5,044,638$439Mincrease2026-06-30
Vanguard Capital Management LLC4,172,482$363Mincrease2026-06-30
Parallel Advisors, LLC3,962,177$345Mdecrease2026-06-30
Vanguard Group9,494,822$330Mdecrease2025-12-31
FMR LLC3,337,618$290Mincrease2026-06-30
State Street3,279,381$285Mincrease2026-06-30
AQR Capital Management LLC2,582,561$225Mincrease2026-06-30
Geode Capital Management, LLC2,532,198$220Mdecrease2026-06-30
First Trust Advisors LP1,829,545$159Mdecrease2026-06-30
Tang Capital Management LLC1,500,000$130Munchanged2026-06-30
UBS Group AG1,377,658$120Mincrease2026-06-30
Dimensional Fund Advisors LP1,318,821$115Mdecrease2026-06-30

Corcept Therapeutics' latest quarter

Corcept Therapeutics, Q3 2026: revenue $340M (+64% year over year), operating margin 33.7%, net earnings $127M, operating cash flow $143M. The chart follows the revenue to costs, profit and cash.

Questions

Who owns the most CORT stock?

By the latest 13F filings: BlackRock ($1.1B); Ingalls & Snyder LLC ($690M); Renaissance Technologies LLC ($457M); Vanguard Portfolio Management LLC ($439M); Vanguard Capital Management LLC ($363M).

What is the short interest in CORT?

8,588,418 shares were sold short at the 2026-10-15 settlement, 0.56% of the float.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.